Observational Study, for Quality Assessment, of Sarcoma in European and Latin American Multidisciplinary NETWORK
NCT ID: NCT04181970
Last Updated: 2025-03-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
5000 participants
OBSERVATIONAL
2019-06-30
2026-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Expert pathology peer review will be performed to detect differences between expert and non-expert centers as well as differences in treatment and patient prognosis.
Tumor samples of 4 types of sarcoma would also be included in translational research to detect biomarkers and produce preclinical models.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Assessment of the Functional Outcome and Quality of Life in Sarcoma Patients
NCT05051059
Patterns of Care and Outcomes in METAstatic Soft Tissue SARComa
NCT03977818
Status of Surgical Resection and Histologic Subtype as Predictors of Local Recurrence in Retroperitoneal Liposarcoma
NCT05428579
Evaluation of Rare and Complex Tumours of the Thoraco-Abdominal and Soft Tissue District
NCT06872853
Outcomes in Lower Extremity Soft Tissue Sarcoma Patients After Limb Salvage
NCT02536053
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Data registration period includes:
Retrospective part: from January 2012 until June 2019 Prospective part: from July 2019 until January 2022.
In all clinical practice guidelines, it is recommended to refer patients with suspected sarcomas to an Expert Center (EC). The pioneers in implementing EC in sarcomas have been the Scandinavian countries, where referral is mandatory. In Spain, through the Audit of the Ministry of Health, Social Affairs and Equality, 5 CSURs (Centers, Services or Reference Units). Taken together the previous information, and since the European experience in sarcoma EC and sarcoma referral policies have shown to be positive, as numerous outcome indicators favoring patients managed in EC have been reported, a European and Latin-American consortium of sarcoma centers has emerged, supported by Horizon 2020 program (Horizon 2020 Call: H2020-SC1-BHC-2018-2020) with the aim of implementing a process to facilitate the accreditation of expert centers in sarcoma as well as a network of Latin-American sarcoma centers.
A SELNET database is available for all participating countries. to register patient's clinical data: Demographic information, Type of sarcoma (Soft-tissue/Bone/GIST), Clinical presentation, Diagnosis, Treatment, and Survival and follow-up.
Quality of care will be assessed based on the analysis of different diagnostic/therapeutic items, specified in the ESMO-EURACAN clinical practice guidelines:
* Percentage of cases \> 5 cm with tru-cut biopsies.
* Percentage of biopsies carried out by sarcoma teams vs not sarcoma team (in all the series and in cases \> 5 cm).
* Percentage of patients with image studies at diagnosis and before surgery.
* Percentage of patients discussed in multidisciplinary teams (MDT) before treatment.
* Percentage of patients with specified histopathological grade in pathologic report.
* Percentage of affected surgical margins in first surgery.
* Percentage of re-resections in patients with affected surgical margins in first surgery.
* Co-adjuvant therapies: percentage of patients with \>5 cm, G2-3 sarcoma receiving neo/adjuvant radiotherapy.
* Percentage of patients with localized GIST with adequate risk assessment (specified mitotic count (50HPF), site and size of primary tumor).
* Percentage of patients with advanced GIST with available molecular status of KIT/PDGFR before initiating systemic therapy for advanced disease.
* Percentage of patients with regular follow-up.
For the localised disease quality assessment, we'll focus on:
* Surgical margins will be correlated with: Type of biopsy, team performing diagnostic biopsy, preoperative image studies and discussion in MDT.
* Relapse-free survival will be correlated with type of biopsy, team performing diagnostic biopsy, discussion in MDT, surgical margins status, re-resection performance, co-adjuvant therapies
* Overall survival will be correlated with team performing diagnostic biopsy, discussion in MDT, surgical margins status, re-resection performance, coadjuvant therapies
* Percentage of amputation will be correlated with type of biopsy, team performing diagnostic biopsy, discussion in MDT, surgical margins status.
* Long-term side effects will be correlated with type of surgery, team performing diagnostic biopsy, discussion in MDT, surgical margins status, co-adjuvant therapies.
For advance disease quality assessment, we'll focus on:
* Progression-free survival will be correlated with discussion in MDT, type of center (expert/not)
* Overall survival will be correlated with discussion in MDT, access to clinical trials, access to second lines, surgery of metastatic disease, type of center (expert/not)
An expert pathology review will take place to diagnose sarcoma cases and evaluate the differences in diagnosis and it outcome and consequences.
Four sarcoma subtypes have been selected to analyse further with biological tissue samples.: Angiosarcoma, Desmoplastic Small Round Cell Tumor, Extraskeletal myxoid chondrosarcoma and Solitary fibrous tumors. The aims of the translational research program are: to describe prognostic factors and/ or cell signaling pathways of relevance in AS, DSRCT, EMC and SFT; to describe predictive biomarkers of first and second line agents; to study the potential mechanisms of action of first and second line agents and their role in the activation of antitumor tumor microenvironment (e.g. immune response) and to establish preclinical models on these rare subtypes of sarcoma to validate OMICs data. This will open new doors for novel hypothesis for clinical trials based on the analysis of differential gene expression, cell signaling pathways and/ or predictive biomarkers.
Progression Free Survival (PFS), objective tumor response, Overall survival (OS), and histopathological features will be correlated with OMICs data.
Samples to collect:
* Tumor blocks will be used to analyze protein fusion (by NGS), RNA expression (by RNA-Seq) and protein expression (by IHC). The tumors samples will be collected from the diagnostic time. If available, paired tumor samples will be shipped to determine the differential gene expression of post-treatment specimens.
* Prospective fresh tumor samples will be used for whole genome sequencing and to establish PDX and 3D tumor organoid-like models, at translational central laboratories (SFT: Seville; EMC: Milan; AS: Lyon; DSRCT; Sao Paulo).Moreover, fresh tumor samples could also be collected, from national associated centers, and shipped frozen to national central laboratory. Frozen tumors will be shipped in 10% DMSO - 90% FBS, which preserves quite well tumor cell viability.
All patients should sign and date the Informed Consent Form after reading the patient Information Sheet to accept participating in this study. Participating in the study is voluntary and the patient can withdraw his/her consent at any time, without giving any reason and without reducing his/her right to health care.
He/she can also withdraw the consent to use the tumor sample donated to the study without withdrawing the participation in the study (the patient's clinical data will be registered and analysed). If this happens, the tumor sample left in the central laboratory can be returned to the origin site. Any withdraw should be confirmed by signing a Revocation Form. However, the investigator should try to know the reason to withdraw consent in order to improve the study conditions.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
OTHER
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Quality assessment
There is no intervention on study subjects. A tumor review will be performed by expert centers.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* ≥ 18 years
* Available clinical and treatment information
18 Years
120 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Grupo Espanol de Investigacion en Sarcomas
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Javier MARTIN-BROTO, MD
Role: PRINCIPAL_INVESTIGATOR
Salud de Madrid
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Alexander Fleming Sa
Buenos Aires, , Argentina
A C Camargo
São Paulo, , Brazil
Hospital San Vicente de Paúl
Heredia, , Costa Rica
Centre Leon Berard
Lyon, , France
Instituto Ortopedico Rizzoli
Bologna, , Italy
Insituto Nazionale Di Tumore
Milan, , Italy
Instituto Nacional de Cancerología
Mexico City, , Mexico
Instituo Nacional de enfermedades Neoplásicas
Surquillo, , Peru
Fundación Jiménez Díaz
Madrid, Madrid, Spain
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SELNET (GEIS 68)
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.